These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

9277 related articles for article (PubMed ID: 1874515)

  • 1. Aglycosylated chimeric mouse/human IgG1 antibody retains some effector function.
    Dorai H; Mueller BM; Reisfeld RA; Gillies SD
    Hybridoma; 1991 Apr; 10(2):211-7. PubMed ID: 1874515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells.
    Wright A; Morrison SL
    J Immunol; 1998 Apr; 160(7):3393-402. PubMed ID: 9531299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding and functional properties of a mouse-human chimeric monoclonal antibody of the human IgG1 subclass with specificity for human carcinomas.
    Liao SK; Horton L; Flahart RE; O'Rear L; Crumpacker D; Imbaratto JW; Yannelli JR; Robinson RR; Oldham RK
    Hum Antibodies Hybridomas; 1990; 1(2):66-76. PubMed ID: 2103354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
    Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
    Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors.
    Gillies SD; Lan Y; Lo KM; Super M; Wesolowski J
    Cancer Res; 1999 May; 59(9):2159-66. PubMed ID: 10232603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region.
    Tao MH; Morrison SL
    J Immunol; 1989 Oct; 143(8):2595-601. PubMed ID: 2507634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative biological properties of a recombinant chimeric anti-carcinoma mAb and a recombinant aglycosylated variant.
    Hand PH; Calvo B; Milenic D; Yokota T; Finch M; Snoy P; Garmestani K; Gansow O; Schlom J; Kashmiri SV
    Cancer Immunol Immunother; 1992; 35(3):165-74. PubMed ID: 1638552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric anti-ganglioside GM2 antibody with antitumor activity.
    Nakamura K; Koike M; Shitara K; Kuwana Y; Kiuragi K; Igarashi S; Hasegawa M; Hanai N
    Cancer Res; 1994 Mar; 54(6):1511-6. PubMed ID: 8137257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
    Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
    Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal combination of beneficial mutations for improved ADCC effector function of aglycosylated antibodies.
    Yoon HW; Jo M; Ko S; Kwon HS; Lim CS; Ko BJ; Lee JC; Jung ST
    Mol Immunol; 2019 Oct; 114():62-71. PubMed ID: 31336250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric interleukin 2 receptor alpha chain antibody derivatives with fused mu and gamma chains permit improved recruitment of effector functions.
    Schäffner M; François C; Kaluza B; Hock H; Jacques Y; Weidle UH
    Mol Immunol; 1995 Jan; 32(1):9-20. PubMed ID: 7870061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a mouse/human chimeric monoclonal antibody (17-1A) to a colon cancer tumor-associated antigen.
    Shaw DR; Khazaeli MB; Sun LK; Ghrayeb J; Daddona PE; McKinney S; LoBuglio AF
    J Immunol; 1987 Jun; 138(12):4534-8. PubMed ID: 3584980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities.
    Gillies SD; Wesolowski JS
    Hum Antibodies Hybridomas; 1990; 1(1):47-54. PubMed ID: 2129419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1.
    Wright A; Morrison SL
    J Exp Med; 1994 Sep; 180(3):1087-96. PubMed ID: 8064227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of inter-heavy and light chain disulfide bonds in the effector functions of human immunoglobulin IgG1.
    Dorai H; Wesolowski JS; Gillies SD
    Mol Immunol; 1992 Dec; 29(12):1487-91. PubMed ID: 1454066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity.
    Liu AY; Robinson RR; Murray ED; Ledbetter JA; Hellström I; Hellström KE
    J Immunol; 1987 Nov; 139(10):3521-6. PubMed ID: 3119711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IgG isotype conversion of a novel human anti-carcinoembryonic antigen antibody to increase its biological activity.
    Huang J; Shibaguchi H; Zhao J; Luo N; Kuroki M; Kinugasa T; Hirose Y; Yamada H; Kuroki M
    Anticancer Res; 2006; 26(2A):1057-63. PubMed ID: 16619506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of domain deletion, glycosylation, and long IgG3 hinge on the biodistribution and serum stability properties of a humanized IgG1 immunoglobulin, hLL2, and its fragments.
    Leung SO; Qu Z; Hansen HJ; Shih LB; Wang J; Losman MJ; Goldenberg DM; Sharkey RM
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3106s-3117s. PubMed ID: 10541351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of VK framework-1 glycosylation on the binding affinity of lymphoma-specific murine and chimeric LL2 antibodies and its potential use as a novel conjugation site.
    Leung SO; Dion AS; Pellegrini MC; Losman MJ; Grebenau RC; Goldenberg DM; Hansen HJ
    Int J Cancer; 1995 Feb; 60(4):534-8. PubMed ID: 7829269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.
    Grevys A; Bern M; Foss S; Bratlie DB; Moen A; Gunnarsen KS; Aase A; Michaelsen TE; Sandlie I; Andersen JT
    J Immunol; 2015 Jun; 194(11):5497-508. PubMed ID: 25904551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 464.